SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors react to the company's deepening ties with U.S. government defense and space initiatives, including high-profile Quantum Technology Showcases in Washington. Community sentiment remains polarized, with many users debating whether current valuation levels represent a generational buying opportunity or a warning sign given the intense volatility in the broader quantum sector.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending as investors react to reports of impending foundry price hikes and continued robust demand for advanced manufacturing capacity. The community is closely watching upcoming monthly sales data and company updates as critical indicators of whether the firm can sustain its leadership amid ongoing semiconductor supply bottlenecks.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors aggressively discuss anticipated Q2 revenue pre-announcements and global expansion efforts while tracking a massive short position. The community is actively debating the impact of upcoming clinical trial catalysts and potential institutional accumulation despite persistent downward price pressure.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is experiencing high volatility as investors debate the company's aggressive capital expenditures in AI infrastructure, with recent news of the 'Muse Spark 1.1' model release and in-house chip manufacturing sparking a sharp intraday price reversal. The community is actively split between bullish sentiment over long-term AI scaling and concerns regarding the potential for profit-taking or further market corrections following recent price fluctuations.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is facing heightened community debate as investors weigh speculative hype against concerns over supply inflation and price volatility. Discussion remains polarized, with many users debating whether current price action signals a bottom for accumulation or a persistent trap for retail holders.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is drawing investor attention as it prepares to present new clinical data on its ITK inhibitor, soquelitinib, at upcoming medical conferences. While some community members highlight the potential of its immune-modulating pipeline and recent insider buying as bullish catalysts, others remain skeptical about the company's long-term commercialization strategy and the competitive pressures from major pharmaceutical players in the immunology space.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the stock's significant decline presents a deep-value buying opportunity or a deeper structural issue following negative growth commentary and concerns over share price volatility. The community is actively tracking institutional accumulation, recent insider buying, and the conclusion of an accelerated share repurchase program, while weighing these against ongoing sector rotation out of healthcare and into higher-momentum tech sectors.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

UniSwap is generating intense community buzz following the UNIfication proposal, which aims to activate a fee switch for revenue sharing and execute a massive 100 million token burn. Traders are closely monitoring the technical setup as the potential for deflationary tokenomics fuels speculation about a sustained upward breakout.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as market participants debate the impact of potential regulatory clarity, specifically the proposed Clarity Act, alongside ongoing discussions about institutional accumulation and geopolitical tensions. Community members are actively analyzing technical charts and macroeconomic catalysts to determine if current price levels represent a bottom or a precursor to further volatility.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is seeing significant investor attention following the FDA's grant of Fast Track designation for its chronic hepatitis B candidate, imdusiran, alongside ongoing monitoring of institutional accumulation and pending patent litigation outcomes. The community is actively discussing the company's valuation, potential strategic partnerships or buyout scenarios, and frustration regarding the lack of proactive communication from leadership following the recent Moderna settlement.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger PR Newswire NEW YORK, July 6, 2026 NEW YORK, July 6, 2026 /PRNewswire/ --Translational Development Acquisition Company (NYSE: TDAC) ( "TDAC...

TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote

TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote PR Newswire NEW YORK, June 22, 2026 85% of Shares are not Redeemed, resulting in TDAC maintaining $156.8mm in trust95...

Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY.

Translational Development Acquisition Corp. - Ordinary Shares- Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

TDACTranslational Development Acquisition Corp.

Fundamentals

Latest TDAC News